TGTX
Closed
Tg Therapeutics Inc
35.4
-0.6 (-1.67%)
Last Update: 01 Jul 2025 23:05:00
Yesterday: 35.99
Day's Range: 35.1 - 36.9099
Send
sign up or login to leave a comment!
When Written:
21.93
TG Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing innovative treatments for B-cell malignancies and autoimmune diseases. The company's lead product candidate is ublituximab, a novel monoclonal antibody that targets a specific protein on the surface of B-cells, which are the immune cells responsible for producing antibodies. Ublituximab is being developed for the treatment of various B-cell malignancies, including chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), and multiple myeloma. The company also has a pipeline of other product candidates, including umbralisib, a PI3K delta inhibitor, and TG-1701, a BTK inhibitor, both of which are being developed for the treatment of B-cell malignancies and autoimmune diseases. TG Therapeutics was founded in 1993 and is headquartered in New York City.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








